Sorrento Therapeutics (SRNE) stock price, revenue, and financials

Sorrento Therapeutics market cap is $368.9 m, and annual revenue was $21.19 m in FY 2018

$368.9 M

SRNE Mkt cap, 10-Jun-2019

$6.1 M

Sorrento Therapeutics Revenue Q1, 2019
Sorrento Therapeutics Gross profit (Q1, 2019)3.8 M
Sorrento Therapeutics Gross profit margin (Q1, 2019), %62.4%
Sorrento Therapeutics Net income (Q1, 2019)-146.5 M
Sorrento Therapeutics EBIT (Q1, 2019)-123.2 M
Sorrento Therapeutics Cash, 31-Mar-201991 M

Sorrento Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

460.1k3.8m4.6m8.2m151.9m21.2m

Revenue growth, %

731%20%78%

Cost of goods sold

2.0m811.0k3.9m7.1m

Gross profit

2.6m7.3m147.9m14.1m

Gross profit Margin, %

58%90%97%67%

R&D expense

9.0m24.0m31.3m42.2m55.5m77.0m

General and administrative expense

6.3m10.0m20.1m24.2m38.3m63.6m

Operating expense total

22.1m34.0m78.6m104.9m126.5m171.6m

EBIT

(21.7m)(34.7m)(74.0m)(96.8m)25.3m(150.4m)

EBIT margin, %

(4709%)(908%)(1612%)(1187%)17%(710%)

Interest expense

253.2k1.6m1.7m1.6m5.0m57.6m

Interest income

9.6k12.0k24.0k272.0k241.0k921.0k

Pre tax profit

(13.8m)(64.8m)15.3m

Income tax expense

(1.7m)36.3m(896.0k)(36.0m)(6.3m)

Net Income

(21.9m)(34.7m)(50.1m)(63.9m)11.1m(212.5m)

Sorrento Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

31.7m71.9m39.0m82.4m20.4m158.7m

Current Assets

32.6m73.9m141.0m89.7m29.7m179.6m

PP&E

2.4m2.3m7.2m12.7m19.3m24.4m

Goodwill

24.0m24.0m20.6m41.5m38.3m38.3m

Total Assets

92.6m141.5m343.5m401.6m431.6m624.1m

Accounts Payable

2.2m1.7m1.3m8.3m9.9m13.8m

Current Liabilities

5.5m9.6m30.9m76.1m79.0m61.6m

Long-term debt

4.4m8.8m4.4m47.1m

Total Debt

47.1m

Total Liabilities

315.1m225.0m416.6m

Additional Paid-in Capital

99.7m176.2m184.9m303.9m413.9m626.7m

Retained Earnings

(67.5m)(113.3m)(174.3m)(165.1m)(367.7m)

Total Equity

66.8m108.7m140.9m86.5m206.6m207.5m

Debt to Equity Ratio

0.5 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.4 x1.3 x2.4 x4.6 x2.1 x3 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

6.4m29.9m50.2m44.3m60.5m51.7m59.1m20.8m98.2m66.5m33.9m53.7m38.3m24.3m46.8m135.4m91.0m

Inventories

4.6m

Current Assets

6.9m31.2m51.4m45.8m62.2m53.8m124.8m71.7m146.3m71.8m42.1m60.6m44.7m36.6m54.7m145.2m118.6m

PP&E

1.7m2.4m2.3m2.4m2.5m2.8m3.8m7.4m9.2m10.1m17.0m18.0m19.0m19.5m19.9m21.5m28.9m

Goodwill

24.0m24.0m24.0m24.0m12.5m20.6m20.6m20.6m20.6m36.9m38.3m38.3m38.3m38.3m38.3m38.3m

Total Assets

38.0m90.6m110.3m104.1m131.3m132.8m325.3m273.8m351.4m279.1m345.2m384.8m484.8m436.9m452.5m588.0m609.5m

Accounts Payable

1.4m1.2m1.3m1.5m1.9m2.5m1.6m3.1m4.4m1.4m11.6m9.6m13.0m9.0m9.9m17.2m14.7m

Current Liabilities

2.3m5.3m6.9m8.7m9.4m10.4m26.1m28.4m61.0m36.0m71.8m79.3m83.4m51.5m39.4m82.4m74.1m

Long-term debt

4.8m10.3m9.4m8.4m7.7m6.9m5.6m3.1m1.8m458.0k26.1m26.5m24.6m5.5m16.2m145.5m

Total Debt

4.8m10.3m9.4m8.4m7.7m6.9m5.6m3.1m1.8m458.0k26.1m26.5m24.6m5.5m16.2m145.5m

Total Liabilities

41.6m178.5m184.8m216.2m206.6m283.1m288.6m346.5m196.0m193.1m364.4m491.4m

Additional Paid-in Capital

52.4m102.1m129.4m130.0m178.0m180.2m181.7m189.8m337.0m336.6m304.6m353.2m357.9m480.7m574.3m588.9m657.1m

Retained Earnings

(59.0m)(78.0m)(88.9m)(89.9m)(131.7m)(176.7m)(162.3m)(197.3m)(211.5m)(177.5m)(196.8m)(270.6m)(318.0m)(475.8m)

Total Equity

30.9m59.2m78.0m71.0m100.0m91.3m146.8m89.0m135.2m72.5m62.1m96.2m138.3m240.9m259.5m223.6m118.1m

Debt to Equity Ratio

0.2 x0.2 x0.1 x0.1 x0.1 x0 x0 x0 x0 x0.4 x0.3 x0.2 x0 x0.1 x0.7 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0 x0 x0 x0 x0.1 x0.1 x0.1 x0 x0 x0.2 x

Financial Leverage

1.2 x1.5 x1.4 x1.5 x1.3 x1.5 x2.2 x3.1 x2.6 x3.8 x5.6 x4 x3.5 x1.8 x1.7 x2.6 x5.2 x

Sorrento Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(21.9m)(34.7m)(50.1m)(63.9m)11.1m(212.5m)

Depreciation and Amortization

1.3m3.2m2.4m2.9m7.1m9.1m

Accounts Receivable

(2.2m)

Inventories

(3.2m)

Accounts Payable

878.6k(497.0k)(2.7m)3.7m1.6m3.6m

Cash From Operating Activities

(16.5m)(28.8m)(42.1m)(70.9m)(99.2m)(111.8m)

Purchases of PP&E

(420.2k)(591.0k)(3.7m)(6.9m)(11.0m)(11.2m)

Cash From Investing Activities

(503.5k)(10.6m)12.6m(17.5m)(16.5m)(21.2m)

Cash From Financing Activities

43.6m79.6m(3.3m)131.7m53.7m326.0m

Interest Paid

1.5m1.6m1.3m3.5m1.6m

Income Taxes Paid

800.06.0k3.0m2.0k34.0k6.0k

Sorrento Therapeutics Ratios

USDY, 2019

Financial Leverage

5.2 x

Sorrento Therapeutics Employee Rating

2.519 votes
Culture & Values
2.5
Work/Life Balance
2.6
Senior Management
1.9
Salary & Benefits
2.1
Career Opportunities
2.8
Source